NVS · Novartis
AI read · Bad for NVS
The AI's read
The failed main goal weakens the case for pelacarsen in Novartis's heart-disease drug program. More details are coming, but they do not change the reported failure.
Novartis said its Phase III ORION-4 trial for pelacarsen did not meet its main goal.
Bad for NVS
Novartis's pelacarsen trial missed its main goal, weakening the outlook for this drug program. Full findings are still due later, but they do not change the reported failure.
Get alerts for NVS
Follow Novartis (NVS) free. When we publish a story about it, you get the plain-English explanation as an alert.
Get alerts for NVSFree on the App Store and Google Play, or on the web.